In combination with shikonin, ipilimumab significantly enhanced CD3+CD4+ T cells in adherent cell lines of SKRC-17 and RCC-53, atezolizumab significantly elevated the CD3+CD4+ T cells population in SKRC-17 adherent cells and its CSCs as well as in RCC-53 CSCs. The gene discussed is CD4; the disease is renal cell carcinoma.